Autres langues Genenta Science S.p.A.

Actions

GNTA

US36870W1009

Temps Différé Nasdaq Autres places de cotation 16:34:13 29/04/2024			Varia. 5j.	Varia. 1 janv.
2,55 ^USD	-1,54 %		-35,39 %	-48,48 %

08/04	Genenta Science S.P.A. annonce la démission de membres du conseil d'administration	CI
29/03	Genenta Science S.p.A. publie ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Genenta Science S.P.A. Announces Resignation of Board Members	08/04
Genenta Science S p A : NOTICE OF CALL OF THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS’ MEETING - Form 6-K	02/04
Genenta Science S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors	08/02
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors	08/02
Genenta Science Demonstrated Reprogramming of the Tumor Microenvironment in Gbm Patients, Paving the Way for Innovative Treatments of Solid Tumors	08/02
Sandoz kauft Medikament Cimerli für 170 Millionen US-Dollar von Coherus	22/01
Sandoz to Acquire Cimerli Business from Coherus for $170 Million	22/01
Genenta Science S p A : Consolidated Statements of Operations and Comprehensive Loss - Form 6-K	20/10/23
Genenta Science S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2023	20/10/23
Genenta to Present at Upcoming Scientific and Investor Conferences	06/09/23
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments	28/07/23
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments	28/07/23
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments	28/07/23
The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma	29/06/23
Health Care Stocks Support American Depositary Receipts of European Equities	16/06/23
Genenta to Provide Update on Lead Product Temferon™	16/05/23
Genenta Science S p A : NOTICE OF CALL OF THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS’ MEETING - Form 6-K	10/05/23
Genenta Science S p A : Effectiveness of the Amended and Restated OSR License Agreement - Form 6-K	01/05/23
Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing	26/04/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Genenta Science S.p.A.

Actions

GNTA

US36870W1009

Autres langues

Filtres